Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. Alercell is a true innovator, disruptor, and leader in the field of preventative oncology. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide. Alercell's mission is to make a difference in the fight against cancer by providing innovative and accurate diagnostic solutions that improve patient outcomes.
Dr. Frederic Scheer is a highly accomplished executive with a remarkable history of success in both private and public enterprises. With a rich reservoir of executive expertise, Mr. Scheer plays a pivotal role in shaping the corporate development and strategic direction of Alercell. His impressive track record includes guiding numerous startups to listings on major stock exchanges such as Nasdaq.
As the visionary founder of several pioneering ventures, including Interpart, the Biodegradable Products Institute, Cereplast, Biocorp, and Alercell, Dr. Scheer has made significant contributions to the fields of sustainability, biotechnology, and molecular diagnostics. His innovative work is exemplified by 15 US patents in Biotechnology, three of which pertain to cutting-edge nano particle technology.
Currently serving as the Founder and CEO of Alercell, Inc., Dr. Scheer leads this molecular diagnostic company with a strong focus on oncology diagnostics and prevention, furthering advancements in the medical field.
Outside of the corporate world, Dr. Scheer's commitment to making a positive impact is evident in his leadership of The Scheer Foundation, a non-profit 501(c)3 organization dedicated to combating malnutrition in Africa. His multifaceted career and philanthropic efforts showcase a remarkable blend of entrepreneurial acumen and social responsibility.
Michael Okada, CPA, is a Senior financial executive and “Big 4” CPA with over 30 years of successful experience in growth-oriented entrepreneurial companies with revenues from $10 million up to $1+ billion. Mr. Okada has over 30 years of experience in corporate finance for private and public companies. He served as CFO of Alercell since 2020. Mr. Okada earned a Bachelor of Science degree in Accounting from Santa Clara University.
Chief Medical Officer - Dr. Alexandre Scheer, MD co-founders of Alercell and currently serves as Alercell CMO. Dr. Scheer specialized in the evaluation and management of persistent pain related to orthopedic injuries. He also specialized in PRP (Platelets Rich Plasma) injections as well as Stem Cells injections. Dr. Scheer is a surgeon and did two years of neurosurgery at Albert Einstein College of Medicine Beth Israel Medical Center Department of Surgery in New York. Dr. Scheer graduated from UCLA. Dr. Scheer is the son of Frederic Scheer.
Senior Executive Vice President Hematology -Dr. Elina Tsyvkin received her MD from University of Moscow (Russia), followed by residency at Tuff University and Umass University. Dr Tsyvkin is working at Sloan Kettering Memorial where she has been holding a position in hematology malignancies/Leukemia. Dr Tsyvkin has over 25 years of experience in Hematology malignancy. Dr. Tsyvkin is associate Professor at Cornell University Medical School.
Senior Executive Vice President Nanotechnology- Neuroscience - Dr. Gleb Sukhorukov has over 25 years of experience in the field of biopolymers, after obtaining his PhD from University of Moscow, he joined Queen’s Mary University where he now holds the Chair of Biopolymers in technology. He has led several recognizable projects in the field of medicine and biopolymers and is specialized in nanoparticles. He holds over 18 patents in various sectors.
Executive Vice President Core Laboratory Diagnostics - Dr. Donna Mendes obtained her MD from Colombia University College of Physicians & Surgeons in New York City. She is an associate Professor of Surgery at Mount Sinai School of Medicine. Internationally recognized for starting hemodialysis centers in Bermuda thus preventing residents from traveling to the United States for access procedures. Dr Mendes is Nationally recognized as the first African American female vascular surgeon to be certified by the American Board of Surgery in Vascular Surgery; Dr. Mendes was inducted into the Library of Congress.
Executive Vice President Molecular Diagnostics - Dr. Christopher Johnson, MD. graduated from Harvard Medical School, Dr. Johnson also obtained an MCs in Biochemistry at Oxford University (UK). Since 2001 Dr. Johnson has had his own surgery practice in California / New York and Bermuda. Dr. Johnson published several research papers on Cellular studies of the etiology of abdominal aortic aneurysms and on Nuclear magnetic resonance studies of oligosaccharides isolated from fetal meconium and bovine colostrum.
Executive Vice President Sales & Marketing North America - Mr. Darin DeLong received his BS from Mansfield University (PA) Mr. Delong Graduated from Mansfield University (PA) and has worked for over 25 years in the medical field in Fortune 500 companies in various capacity in sales & marketing. Mr. DeLong has been associated with Alercell since its inception and oversees medical supply distribution.
Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide. Alercell is focused on two segments: Oncology & Neuroscience
Alercell has 2 subsidiaries:
Alercell UK and Alercell France.
Alercell Oncology launched in January 2023 Lena Q51 the very first Leukemia diagnostic test able to detect up to 51 genes mutations. Genes mutations in Leukemia is a significant biomarker indication of the disease.
Alercell Oncology also launched a new Leukemia platform: Lena dx Leukemia platform, regrouping 12 Diagnostic tests to target Leukemia diagnostic at its earliest stage.
Alercell also intends to launch soon Lena S1, a Lung cancer early diagnostic test based on DNA Methylation
Alercell Neuroscience aims to create a nanoparticle neural interface for recording and controlling brain activity with the ultimate goal to find solutions for neurodegenerative diseases such as dementia or Alzheimer.
The Alercell mission is built on the foundation of “stopping it before it starts”. Our genetics based testing is the first line of assault against cancer & leukemia and infectious disease. We utilize cutting edge technology such as DNA sequencing to develop a myriad of rapid testing tools that are used to discover major disease in the earliest stages. Every new innovation grows from a driving principle of prevention through discovery.
Delos M. Cosgrove, MD